A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
Identifieur interne : 000B60 ( PubMed/Checkpoint ); précédent : 000B59; suivant : 000B61A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
Auteurs : Ali A. Rabaan [Arabie saoudite] ; Shamsah H. Alahmed [Arabie saoudite] ; Ali M. Bazzi [Arabie saoudite] ; Hatem M. Alhani [Arabie saoudite]Source :
- Journal of medical microbiology [ 1473-5644 ] ; 2017.
Descripteurs français
- KwdFr :
- Antiviraux (usage thérapeutique), Cathepsine L (antagonistes et inhibiteurs), Coronavirus du syndrome respiratoire du Moyen-Orient (), Coronavirus du syndrome respiratoire du Moyen-Orient (génétique), Coronavirus du syndrome respiratoire du Moyen-Orient (isolement et purification), Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie), Humains, Infections à coronavirus (), Infections à coronavirus (virologie), Inhibiteurs de la sérine protéinase (usage thérapeutique), Interactions hôte-pathogène, Interférons (usage thérapeutique), Serine endopeptidases (métabolisme), Vaccins antiviraux (administration et posologie), Vaccins antiviraux (usage thérapeutique), Études prospectives.
- MESH :
- administration et posologie : Vaccins antiviraux.
- antagonistes et inhibiteurs : Cathepsine L.
- génétique : Coronavirus du syndrome respiratoire du Moyen-Orient.
- isolement et purification : Coronavirus du syndrome respiratoire du Moyen-Orient.
- métabolisme : Serine endopeptidases.
- physiologie : Coronavirus du syndrome respiratoire du Moyen-Orient.
- usage thérapeutique : Antiviraux, Inhibiteurs de la sérine protéinase, Interférons, Vaccins antiviraux.
- virologie : Infections à coronavirus.
- Coronavirus du syndrome respiratoire du Moyen-Orient, Humains, Infections à coronavirus, Interactions hôte-pathogène, Études prospectives.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Cathepsin L (antagonists & inhibitors), Coronavirus Infections (therapy), Coronavirus Infections (virology), Host-Pathogen Interactions, Humans, Interferons (therapeutic use), Middle East Respiratory Syndrome Coronavirus (drug effects), Middle East Respiratory Syndrome Coronavirus (genetics), Middle East Respiratory Syndrome Coronavirus (isolation & purification), Middle East Respiratory Syndrome Coronavirus (physiology), Prospective Studies, Serine Endopeptidases (metabolism), Serine Proteinase Inhibitors (therapeutic use), Viral Vaccines (administration & dosage), Viral Vaccines (therapeutic use).
- MESH :
- chemical , administration & dosage : Viral Vaccines.
- chemical , antagonists & inhibitors : Cathepsin L.
- chemical , metabolism : Serine Endopeptidases.
- chemical , therapeutic use : Antiviral Agents, Interferons, Serine Proteinase Inhibitors, Viral Vaccines.
- drug effects : Middle East Respiratory Syndrome Coronavirus.
- genetics : Middle East Respiratory Syndrome Coronavirus.
- isolation & purification : Middle East Respiratory Syndrome Coronavirus.
- physiology : Middle East Respiratory Syndrome Coronavirus.
- therapy : Coronavirus Infections.
- virology : Coronavirus Infections.
- Host-Pathogen Interactions, Humans, Prospective Studies.
Abstract
There have been 2040 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 34.9 %. There is no specific therapy. The current therapies have mainly been adapted from severe acute respiratory syndrome (SARS-CoV) treatments, including broad-spectrum antibiotics, corticosteroids, interferons, ribavirin, lopinavir-ritonavir or mycophenolate mofetil, and have not been subject to well-organized clinical trials. The development of specific therapies and vaccines is therefore urgently required. We examine existing and potential therapies and vaccines from a molecular perspective. These include viral S protein targeting; inhibitors of host proteases, including TMPRSS2, cathepsin L and furin protease, and of viral M(pro) and the PL(pro) proteases; convalescent plasma; and vaccine candidates. The Medline database was searched using combinations and variations of terms, including 'Middle East respiratory syndrome coronavirus', 'MERS-CoV', 'SARS', 'therapy', 'molecular', 'vaccine', 'prophylactic', 'S protein', 'DPP4', 'heptad repeat', 'protease', 'inhibitor', 'anti-viral', 'broad-spectrum', 'interferon', 'convalescent plasma', 'lopinavir ritonavir', 'antibodies', 'antiviral peptides' and 'live attenuated viruses'. There are many options for the development of MERS-CoV-specific therapies. Currently, MERS-CoV is not considered to have pandemic potential. However, the high mortality rate and potential for mutations that could increase transmissibility give urgency to the search for direct, effective therapies. Well-designed and controlled clinical trials are needed, both for existing therapies and for prospective direct therapies.
DOI: 10.1099/jmm.0.000565
PubMed: 28855003
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28855003Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.</title><author><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311</wicri:regionArea><wicri:noRegion>Dhahran 31311</wicri:noRegion></affiliation></author><author><name sortKey="Alahmed, Shamsah H" sort="Alahmed, Shamsah H" uniqKey="Alahmed S" first="Shamsah H" last="Alahmed">Shamsah H. Alahmed</name><affiliation wicri:level="1"><nlm:affiliation>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654</wicri:regionArea><wicri:noRegion>Qatif 32654</wicri:noRegion></affiliation></author><author><name sortKey="Bazzi, Ali M" sort="Bazzi, Ali M" uniqKey="Bazzi A" first="Ali M" last="Bazzi">Ali M. Bazzi</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311</wicri:regionArea><wicri:noRegion>Dhahran 31311</wicri:noRegion></affiliation></author><author><name sortKey="Alhani, Hatem M" sort="Alhani, Hatem M" uniqKey="Alhani H" first="Hatem M" last="Alhani">Hatem M. Alhani</name><affiliation wicri:level="1"><nlm:affiliation>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam</wicri:regionArea><wicri:noRegion>Dammam</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28855003</idno><idno type="pmid">28855003</idno><idno type="doi">10.1099/jmm.0.000565</idno><idno type="wicri:Area/PubMed/Corpus">000A84</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A84</idno><idno type="wicri:Area/PubMed/Curation">000A84</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A84</idno><idno type="wicri:Area/PubMed/Checkpoint">000B60</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B60</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.</title><author><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311</wicri:regionArea><wicri:noRegion>Dhahran 31311</wicri:noRegion></affiliation></author><author><name sortKey="Alahmed, Shamsah H" sort="Alahmed, Shamsah H" uniqKey="Alahmed S" first="Shamsah H" last="Alahmed">Shamsah H. Alahmed</name><affiliation wicri:level="1"><nlm:affiliation>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654</wicri:regionArea><wicri:noRegion>Qatif 32654</wicri:noRegion></affiliation></author><author><name sortKey="Bazzi, Ali M" sort="Bazzi, Ali M" uniqKey="Bazzi A" first="Ali M" last="Bazzi">Ali M. Bazzi</name><affiliation wicri:level="1"><nlm:affiliation>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311</wicri:regionArea><wicri:noRegion>Dhahran 31311</wicri:noRegion></affiliation></author><author><name sortKey="Alhani, Hatem M" sort="Alhani, Hatem M" uniqKey="Alhani H" first="Hatem M" last="Alhani">Hatem M. Alhani</name><affiliation wicri:level="1"><nlm:affiliation>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam</wicri:regionArea><wicri:noRegion>Dammam</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of medical microbiology</title><idno type="eISSN">1473-5644</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Cathepsin L (antagonists & inhibitors)</term><term>Coronavirus Infections (therapy)</term><term>Coronavirus Infections (virology)</term><term>Host-Pathogen Interactions</term><term>Humans</term><term>Interferons (therapeutic use)</term><term>Middle East Respiratory Syndrome Coronavirus (drug effects)</term><term>Middle East Respiratory Syndrome Coronavirus (genetics)</term><term>Middle East Respiratory Syndrome Coronavirus (isolation & purification)</term><term>Middle East Respiratory Syndrome Coronavirus (physiology)</term><term>Prospective Studies</term><term>Serine Endopeptidases (metabolism)</term><term>Serine Proteinase Inhibitors (therapeutic use)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Cathepsine L (antagonistes et inhibiteurs)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient ()</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (génétique)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (isolement et purification)</term><term>Coronavirus du syndrome respiratoire du Moyen-Orient (physiologie)</term><term>Humains</term><term>Infections à coronavirus ()</term><term>Infections à coronavirus (virologie)</term><term>Inhibiteurs de la sérine protéinase (usage thérapeutique)</term><term>Interactions hôte-pathogène</term><term>Interférons (usage thérapeutique)</term><term>Serine endopeptidases (métabolisme)</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (usage thérapeutique)</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cathepsin L</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Serine Endopeptidases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferons</term><term>Serine Proteinase Inhibitors</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Cathepsine L</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Serine endopeptidases</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Middle East Respiratory Syndrome Coronavirus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Inhibiteurs de la sérine protéinase</term><term>Interférons</term><term>Vaccins antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Host-Pathogen Interactions</term><term>Humans</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Coronavirus du syndrome respiratoire du Moyen-Orient</term><term>Humains</term><term>Infections à coronavirus</term><term>Interactions hôte-pathogène</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">There have been 2040 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 34.9 %. There is no specific therapy. The current therapies have mainly been adapted from severe acute respiratory syndrome (SARS-CoV) treatments, including broad-spectrum antibiotics, corticosteroids, interferons, ribavirin, lopinavir-ritonavir or mycophenolate mofetil, and have not been subject to well-organized clinical trials. The development of specific therapies and vaccines is therefore urgently required. We examine existing and potential therapies and vaccines from a molecular perspective. These include viral S protein targeting; inhibitors of host proteases, including TMPRSS2, cathepsin L and furin protease, and of viral M(pro) and the PL(pro) proteases; convalescent plasma; and vaccine candidates. The Medline database was searched using combinations and variations of terms, including 'Middle East respiratory syndrome coronavirus', 'MERS-CoV', 'SARS', 'therapy', 'molecular', 'vaccine', 'prophylactic', 'S protein', 'DPP4', 'heptad repeat', 'protease', 'inhibitor', 'anti-viral', 'broad-spectrum', 'interferon', 'convalescent plasma', 'lopinavir ritonavir', 'antibodies', 'antiviral peptides' and 'live attenuated viruses'. There are many options for the development of MERS-CoV-specific therapies. Currently, MERS-CoV is not considered to have pandemic potential. However, the high mortality rate and potential for mutations that could increase transmissibility give urgency to the search for direct, effective therapies. Well-designed and controlled clinical trials are needed, both for existing therapies and for prospective direct therapies.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28855003</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1473-5644</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>9</Issue><PubDate><Year>2017</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of medical microbiology</Title><ISOAbbreviation>J. Med. Microbiol.</ISOAbbreviation></Journal><ArticleTitle>A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.</ArticleTitle><Pagination><MedlinePgn>1261-1274</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1099/jmm.0.000565</ELocationID><Abstract><AbstractText>There have been 2040 laboratory-confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) in 27 countries, with a mortality rate of 34.9 %. There is no specific therapy. The current therapies have mainly been adapted from severe acute respiratory syndrome (SARS-CoV) treatments, including broad-spectrum antibiotics, corticosteroids, interferons, ribavirin, lopinavir-ritonavir or mycophenolate mofetil, and have not been subject to well-organized clinical trials. The development of specific therapies and vaccines is therefore urgently required. We examine existing and potential therapies and vaccines from a molecular perspective. These include viral S protein targeting; inhibitors of host proteases, including TMPRSS2, cathepsin L and furin protease, and of viral M(pro) and the PL(pro) proteases; convalescent plasma; and vaccine candidates. The Medline database was searched using combinations and variations of terms, including 'Middle East respiratory syndrome coronavirus', 'MERS-CoV', 'SARS', 'therapy', 'molecular', 'vaccine', 'prophylactic', 'S protein', 'DPP4', 'heptad repeat', 'protease', 'inhibitor', 'anti-viral', 'broad-spectrum', 'interferon', 'convalescent plasma', 'lopinavir ritonavir', 'antibodies', 'antiviral peptides' and 'live attenuated viruses'. There are many options for the development of MERS-CoV-specific therapies. Currently, MERS-CoV is not considered to have pandemic potential. However, the high mortality rate and potential for mutations that could increase transmissibility give urgency to the search for direct, effective therapies. Well-designed and controlled clinical trials are needed, both for existing therapies and for prospective direct therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rabaan</LastName><ForeName>Ali A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alahmed</LastName><ForeName>Shamsah H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Specialty Paediatric Medicine, Qatif Central Hospital, Qatif 32654, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazzi</LastName><ForeName>Ali M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Microbiology Laboratory, Johns Hopkins Aramco Healthcare, Dhahran 31311, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhani</LastName><ForeName>Hatem M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Maternity and Children Hospital, and Directorate of Infection Control at Eastern Province, Ministry of Health, Dammam, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Microbiol</MedlineTA><NlmUniqueID>0224131</NlmUniqueID><ISSNLinking>0022-2615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015842">Serine Proteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C421305">TMPRSS2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.15</RegistryNumber><NameOfSubstance UI="C534281">CTSL protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.15</RegistryNumber><NameOfSubstance UI="D056668">Cathepsin L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056668" MajorTopicYN="N">Cathepsin L</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="N">Host-Pathogen Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065207" MajorTopicYN="N">Middle East Respiratory Syndrome Coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015842" MajorTopicYN="N">Serine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral peptide</Keyword><Keyword MajorTopicYN="N">DPP4</Keyword><Keyword MajorTopicYN="N">GLS-5300</Keyword><Keyword MajorTopicYN="N">M(pro)</Keyword><Keyword MajorTopicYN="N">MERS-CoV</Keyword><Keyword MajorTopicYN="N">PL(pro)</Keyword><Keyword MajorTopicYN="N">S protein</Keyword><Keyword MajorTopicYN="N">camostat</Keyword><Keyword MajorTopicYN="N">convalescent plasma</Keyword><Keyword MajorTopicYN="N">glycopeptide antibiotic</Keyword><Keyword MajorTopicYN="N">interferon</Keyword><Keyword MajorTopicYN="N">lopinavir</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">protease</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28855003</ArticleId><ArticleId IdType="doi">10.1099/jmm.0.000565</ArticleId><ArticleId IdType="pmc">PMC7079582</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2013 Dec 04;8(12):e81587</Citation><ArticleIdList><ArticleId IdType="pubmed">24324708</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2016 May 15;213(10):1557-61</Citation><ArticleIdList><ArticleId IdType="pubmed">26941283</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539</Citation><ArticleIdList><ArticleId IdType="pubmed">27550352</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2016 Mar;490:49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">26828465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93</Citation><ArticleIdList><ArticleId IdType="pubmed">24841273</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Clin Virol. 2004 Dec;31(4):304-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15494274</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2010 Apr;84(7):3134-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19906932</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2015 Apr;89(8):4696-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25653445</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Oct;13(10):859-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23933067</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Antimicrob Agents. 2014 Dec;44(6):528-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25288266</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Infect Disord Drug Targets. 2014;14(1):37-43</Citation><ArticleIdList><ArticleId IdType="pubmed">25019238</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Influenza Other Respir Viruses. 2013 Nov;7 Suppl 3:52-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24215382</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15150417</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Aug;88(16):9220-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24899185</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2014 Apr 11;32(18):2100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24560617</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2014;5:3067</Citation><ArticleIdList><ArticleId IdType="pubmed">24473083</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2016 Jun 3;34(26):2982-2987</Citation><ArticleIdList><ArticleId IdType="pubmed">27083424</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virus Erad. 2016;2(1):1-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26866060</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virol J. 2015 Dec 22;12:222</Citation><ArticleIdList><ArticleId IdType="pubmed">26695637</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Feb;14(2):140-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24355866</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Protein Cell. 2013 Dec;4(12):951-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24318862</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):208-12</Citation><ArticleIdList><ArticleId IdType="pubmed">27158023</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2015 Nov;25(11):1237-49</Citation><ArticleIdList><ArticleId IdType="pubmed">26391698</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2016 May 05;6:25359</Citation><ArticleIdList><ArticleId IdType="pubmed">27146253</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2016 Aug 19;6:31629</Citation><ArticleIdList><ArticleId IdType="pubmed">27538452</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Respir Crit Care Med. 2011 May 1;183(9):1207-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21471084</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zhonghua Liu Xing Bing Xue Za Zhi. 2016 Feb;37(2):291-3</Citation><ArticleIdList><ArticleId IdType="pubmed">26917533</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2014 May 1;209(9):1331-42</Citation><ArticleIdList><ArticleId IdType="pubmed">24065148</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1904-13</Citation><ArticleIdList><ArticleId IdType="pubmed">26198719</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2014 Apr 30;6(234):234ra59</Citation><ArticleIdList><ArticleId IdType="pubmed">24778414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Jul;88(14):7796-805</Citation><ArticleIdList><ArticleId IdType="pubmed">24789777</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Crit Care. 2016 May 07;20(1):123</Citation><ArticleIdList><ArticleId IdType="pubmed">27153800</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation><ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2016 Dec 16;91(1):</Citation><ArticleIdList><ArticleId IdType="pubmed">27795425</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2015 Apr;89(7):3859-69</Citation><ArticleIdList><ArticleId IdType="pubmed">25609809</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2015 May 26;6(3):e00638-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26015500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2016 May;15(5):327-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26868298</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2012 Nov 8;367(19):1814-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23075143</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Med. 2013 Oct;19(10):1313-7</Citation><ArticleIdList><ArticleId IdType="pubmed">24013700</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2015 Sep 25;5:14480</Citation><ArticleIdList><ArticleId IdType="pubmed">26404138</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Commun. 2015 Jul 28;6:7712</Citation><ArticleIdList><ArticleId IdType="pubmed">26218507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Viruses. 2012 Jun;4(6):1011-33</Citation><ArticleIdList><ArticleId IdType="pubmed">22816037</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Mol Immunol. 2016 Mar;13(2):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25640653</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunology. 2015 Aug;145(4):476-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25762305</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15226499</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Springerplus. 2015 Nov 19;4:709</Citation><ArticleIdList><ArticleId IdType="pubmed">26618098</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Oct;88(19):11297-303</Citation><ArticleIdList><ArticleId IdType="pubmed">25031349</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>ACS Chem Biol. 2015 Jun 19;10(6):1456-65</Citation><ArticleIdList><ArticleId IdType="pubmed">25746232</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Chest. 2013 Aug;144(2):464-473</Citation><ArticleIdList><ArticleId IdType="pubmed">23450336</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Public Health. 2016 May-Jun;9(3):231-5</Citation><ArticleIdList><ArticleId IdType="pubmed">27102927</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2013 Aug;94(Pt 8):1749-1760</Citation><ArticleIdList><ArticleId IdType="pubmed">23620378</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2013 Mar 14;495(7440):251-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23486063</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2014 Dec 1;59(11):1511-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25100864</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Jun;88(12):7045-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24719424</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Jul;14(7):544-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24964934</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2015 Aug;89(16):8651-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26018172</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2013 Oct;19(10):1697-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24050621</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2013 Sep;13(9):752-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23891402</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Infect Dis. 2015 Feb 1;60(3):369-77</Citation><ArticleIdList><ArticleId IdType="pubmed">25323704</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2014 Mar;20:42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24406736</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>East Mediterr Health J. 2013;19 Suppl 1:S12-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23888790</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2015 Dec 15;212(12):1894-903</Citation><ArticleIdList><ArticleId IdType="pubmed">26164863</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2013 Oct;17(10):e792-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23993766</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2014 May 30;32(26):3169-3174</Citation><ArticleIdList><ArticleId IdType="pubmed">24736006</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2016 Aug;22(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">27439020</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2016 Apr 22;291(17):9218-32</Citation><ArticleIdList><ArticleId IdType="pubmed">26953343</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2015 Apr;116:76-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25666761</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Opin Ther Targets. 2017 Feb;21(2):131-143</Citation><ArticleIdList><ArticleId IdType="pubmed">27936982</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16157-62</Citation><ArticleIdList><ArticleId IdType="pubmed">24043791</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2014 Feb;88(3):1834-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24257613</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2015 Apr 16;202:151-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25445336</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2015 Nov;89(22):11654-67</Citation><ArticleIdList><ArticleId IdType="pubmed">26355094</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2015 Nov;21(11):1981-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26484549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2016 Dec;71(12):3340-3350</Citation><ArticleIdList><ArticleId IdType="pubmed">27585965</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2012 Dec 11;3(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">23232719</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Virol. 2016 Feb;16:55-62</Citation><ArticleIdList><ArticleId IdType="pubmed">26826951</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2017 Jan 12;7:40292</Citation><ArticleIdList><ArticleId IdType="pubmed">28079137</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2012 Nov 20;3(6):</Citation><ArticleIdList><ArticleId IdType="pubmed">23170002</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Respir Med. 2014 Oct;2(10):813-22</Citation><ArticleIdList><ArticleId IdType="pubmed">25174549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Dec;87(23):12552-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24027332</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Intern Med. 2014 Mar 18;160(6):389-97</Citation><ArticleIdList><ArticleId IdType="pubmed">24474051</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2013;3:1686</Citation><ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2015 Dec 14;10(12):e0144865</Citation><ArticleIdList><ArticleId IdType="pubmed">26658006</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Pathog. 2013 Aug;9(8):e1003565</Citation><ArticleIdList><ArticleId IdType="pubmed">23966862</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Infect Dis. 2016 Apr 21;16:174</Citation><ArticleIdList><ArticleId IdType="pubmed">27097824</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Antimicrob Chemother. 2015 Jul;70(7):2129-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25900158</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2013 Aug 1;369(5):407-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23782161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2016 Mar 15;213(6):904-14</Citation><ArticleIdList><ArticleId IdType="pubmed">26203058</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2015 Mar;115:9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">25542975</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2014 Apr;454-455:197-205</Citation><ArticleIdList><ArticleId IdType="pubmed">24725946</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antimicrob Agents Chemother. 2014 Aug;58(8):4875-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24841269</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2008 May;82(9):4420-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18287230</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Transl Med. 2015 Aug 19;7(301):301ra132</Citation><ArticleIdList><ArticleId IdType="pubmed">26290414</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2014 Jan;101:45-56</Citation><ArticleIdList><ArticleId IdType="pubmed">24184128</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2015 Feb 26;372(9):846-54</Citation><ArticleIdList><ArticleId IdType="pubmed">25714162</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>mBio. 2015 Sep 08;6(5):e01280-15</Citation><ArticleIdList><ArticleId IdType="pubmed">26350969</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Exp Immunol. 2004 Mar;135(3):467-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15008980</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Expert Rev Anti Infect Ther. 2017 Mar;15(3):269-275</Citation><ArticleIdList><ArticleId IdType="pubmed">27937060</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2016 May 04;6:25049</Citation><ArticleIdList><ArticleId IdType="pubmed">27142087</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Curr. 2013 Nov 12;5:</Citation><ArticleIdList><ArticleId IdType="pubmed">24270606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS One. 2013 Oct 03;8(10):e76469</Citation><ArticleIdList><ArticleId IdType="pubmed">24098509</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2016 Jan 1;351(6268):77-81</Citation><ArticleIdList><ArticleId IdType="pubmed">26678878</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2014 Sep;109:72-82</Citation><ArticleIdList><ArticleId IdType="pubmed">24992731</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2014 Mar;95(Pt 3):614-626</Citation><ArticleIdList><ArticleId IdType="pubmed">24362959</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15214-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25288733</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2015 Aug 18;5:13133</Citation><ArticleIdList><ArticleId IdType="pubmed">26281793</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Saudi Med. 2014 Sep-Oct;34(5):396-400</Citation><ArticleIdList><ArticleId IdType="pubmed">25827696</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Exp Mol Med. 2015 Aug 28;47:e181</Citation><ArticleIdList><ArticleId IdType="pubmed">26315600</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Ther. 2016;21(5):455-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26492219</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 Dec;87(24):13892-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24067970</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Sci Rep. 2015 Dec 03;5:17554</Citation><ArticleIdList><ArticleId IdType="pubmed">26631542</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2016 Feb 19;65(6):163-4</Citation><ArticleIdList><ArticleId IdType="pubmed">26890816</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antivir Ther. 2015;20(1):87-91</Citation><ArticleIdList><ArticleId IdType="pubmed">24831606</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2013 Dec;94(Pt 12):2679-2690</Citation><ArticleIdList><ArticleId IdType="pubmed">24077366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 2016 Aug;132:141-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27312105</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation><ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2013 May;87(10):5502-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23468491</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Arabie saoudite</li></country></list><tree><country name="Arabie saoudite"><noRegion><name sortKey="Rabaan, Ali A" sort="Rabaan, Ali A" uniqKey="Rabaan A" first="Ali A" last="Rabaan">Ali A. Rabaan</name></noRegion><name sortKey="Alahmed, Shamsah H" sort="Alahmed, Shamsah H" uniqKey="Alahmed S" first="Shamsah H" last="Alahmed">Shamsah H. Alahmed</name><name sortKey="Alhani, Hatem M" sort="Alhani, Hatem M" uniqKey="Alhani H" first="Hatem M" last="Alhani">Hatem M. Alhani</name><name sortKey="Bazzi, Ali M" sort="Bazzi, Ali M" uniqKey="Bazzi A" first="Ali M" last="Bazzi">Ali M. Bazzi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000B60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28855003
|texte= A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28855003" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |